|
|
发表于 30-6-2009 12:12 PM
|
显示全部楼层
昨晚又玩Contra 買進另外2粒，
在閉市前賣出。這星期又有多出的零用錢花了。
 |
|
|
|
|
|
|
|
|
|
|
|
发表于 30-6-2009 12:25 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 30-6-2009 03:08 PM
|
显示全部楼层
好消息：
Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
Last update: 6/30/2009 1:30:00 AM
SEATTLE, June 30, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has been added to the Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes posted by Russell Investments on June 29, 2009 on . Russell Investments reconstitutes its family of U.S. and global equity indexes on an annual basis.
Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the last trading day of May, ranking them by total market capitalization. Membership in the Russell 3000(R) Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. Membership in the Russell Global(R) Index, which remains in place for one year, means automatic inclusion in the appropriate large-cap, small-cap, all-cap indexes as well as the applicable style, sector and country indexes. Russell determines membership for its equity indexes primarily by objective, market capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.
Total returns data for the Russell Indexes is available at .
About Russell
Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell had more than $136 billion in assets under management as of March 31, 2009, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company. About Cell Therapeutics, Inc. Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit . |
|
|
|
|
|
|
|
|
|
|
|
发表于 30-6-2009 05:17 PM
|
显示全部楼层
CTIC
Pre-Market
High 1.69
Last 1.71 |
|
|
|
|
|
|
|
|
|
|
|
发表于 1-7-2009 02:27 AM
|
显示全部楼层
|
密切留意ctic...heb..还留着一些现金。。如果再跌。。再进回一些。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 1-7-2009 04:18 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 1-7-2009 11:37 AM
|
显示全部楼层
CTIC 昨晚賣出後買回，然後最後2分鐘又賣出。
這星期Contra的CTIC給的零用錢不錯下。
|
|
|
|
|
|
|
|
|
|
|
|
发表于 1-7-2009 12:40 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 1-7-2009 02:12 PM
|
显示全部楼层
今晚還會再玩Contra剩余的CTIC。
反正還有今晚（星期3），明晚（星期4）及下星期一。
星期五是美國公共假期沒有股市。
所以 T+5 增加多一天至下星期一。
[ 本帖最后由 葉芬 于 1-7-2009 02:44 PM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 1-7-2009 02:12 PM
|
显示全部楼层
| Date | Open | High | Low | Last | Change | Volume | % Change | | 07/01/09 | 1.75 | 1.78 | 1.65 | 1.72 | -0.06 | 28127328 | -3.37% |
 E
[ 本帖最后由 葉芬 于 1-7-2009 02:38 PM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 1-7-2009 02:13 PM
|
显示全部楼层
| Date | Open | High | Low | Last | Change | Volume | % Change | | 06/30/09 | 1.75 | 1.78 | 1.65 | 1.72 | -0.06 | 28127301 | -3.37% |
| 06/29/09 | 1.69 | 1.85 | 1.67 | 1.78 | -0.07 | 38622500 | -3.78% | | 06/26/09 | 1.55 | 1.90 | 1.51 | 1.85 | +0.28 | 125226602 | +17.83% | | 06/25/09 | 1.45 | 1.57 | 1.41 | 1.57 | +0.08 | 17247500 | +5.37% | | 06/24/09 | 1.52 | 1.54 | 1.45 | 1.49 | +0.08 | 21498602 | +5.67% |
| -- Period -- | -- High -- | -- Low -- | -- Percent Change -- | | 5-Days | 1.90 | on 06/26/09 | 1.41 | on 06/25/09 | +15.44% | since 06/24/09 | | 20-Days | 1.95 | on 06/03/09 | 1.26 | on 06/18/09 | -3.37% | since 06/03/09 | | 65-Days | 2.23 | on 06/01/09 | 0.26 | on 04/13/09 | +377.78% | since 04/01/09 | | 100-Days | 2.23 | on 06/01/09 | 0.01 | on 02/11/09 | +17100.00% | since 02/11/09 | | 260-Days | 2.23 | on 06/01/09 | 0.01 | on 02/11/09 | +265.96% | since 07/02/08 | | Year to Date | 2.23 | on 06/01/09 | 0.01 | on 02/11/09 | +1223.08% | since 01/02/09 |
| For The Last | Made New High | Percent From | Made New Low | Percent From | | 5-Days | 3 time(s) | -9.47% | 2 time(s) | +21.99% | | 20-Days | 1 time(s) | -11.79% | 6 time(s) | +36.51% | | 65-Days | 7 time(s) | -22.87% | 2 time(s) | +561.54% | | 100-Days | 10 time(s) | -22.87% | 1 time(s) | +17100.00% | | 260-Days | 7 time(s) | -22.87% | 27 time(s) | +17100.00% | | Year to Date | 6 time(s) | -22.87% | 9 time(s) | +17100.00% |
[ 本帖最后由 葉芬 于 1-7-2009 02:36 PM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 1-7-2009 02:27 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 3-7-2009 12:11 AM
|
显示全部楼层
原帖由 葉芬 于 1-7-2009 07:15 PM 发表 
CTIC Pre-Market
Low / High / Last 1.71
你contra留的 最后一粒 放了吗？
让我来个马后炮。。。。
russell 3000 《---那么多家公司。。。。
其实 saturated point for CTIC suppose to be 1.85...
所以今天大盘 下了。。当然全部跟着下。。。
没有消息。。。。。。什么股 若是 在大盘下的情况下。。。
往往受到局限。。。。（其实是好事， 不然要怎么买）
下多一点。。。。
那么我可以 收多一些。。。。。
hehhehe.....有钱的人。。股票下了！！ 是时候 monitor+ 进场了。。。。
 |
|
|
|
|
|
|
|
|
|
|
|
发表于 3-7-2009 06:47 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 3-7-2009 01:45 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 3-7-2009 02:11 PM
|
显示全部楼层
要注意下，Next Monday Pre-Market。
聽說有好消息。
聽說的 聽說： 買賣自負。
A BUYOUT OF THE 2 PRODUCTS WHICH COULDsecre at least 200 millions fresh funds and stil a roylty .. the bigcompany has the option already go to google and you will get the name.. ( a kind of alliance partnership) for production and distribution awin win deal
and or a buyout at 5 to 5,50 dol per share
and last possibility imminent approval of pixantron followe by theother oesophage/ ovarian cancer product ( a real response) leading to amuch higher level 10 to 50 doll
[ 本帖最后由 葉芬 于 3-7-2009 02:33 PM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 5-7-2009 09:12 PM
|
显示全部楼层
原帖由 葉芬 于 3-7-2009 02:11 PM 发表 
要注意下，Next Monday Pre-Market。
聽說有好消息。
聽說的 聽說： 買賣自負。
A BUYOUT OF THE 2 PRODUCTS WHICH COULDsecre at least 200 millions fresh funds and stil a roylty .. the bigcompan ...
这消息从哪里看到的啊？
不是很相信。。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 6-7-2009 06:38 PM
|
显示全部楼层
|
CTIC Pre-Market 1.45 -0.15 (-9.37%) |
|
|
|
|
|
|
|
|
|
|
|
发表于 6-7-2009 06:43 PM
|
显示全部楼层
刚刚在yahoo finance 看一下ctic这几天有什么headline, 居然看见
Cell Therapeutics, Inc.
(NasdaqCM: CTIC)
After Hours: 1.45 N/A (N/A) 6:03AM ET
发生什么事情？？
跌了0.15... |
|
|
|
|
|
|
|
|
|
|
|
发表于 7-7-2009 02:40 PM
|
显示全部楼层
PR on Opaxio
European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.'s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
Last update: 7/7/2009 1:30:00 AM
--Potential regulatory approval decision in Q4-2009
SEATTLE, July 7, 2009 /PRNewswire-FirstCall via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it had requested and the EMEA has agreed to an oral explanation in support of the OPAXIO Marketing Authorization Application (MAA) in September, 2009 extending the review for the Committee for Medicinal Products for Human Use (CHMP) opinion on approval until Q4-2009. In April, 2008 the EMEA accepted for review the MAA for OPAXIO for first-line treatment of patients with advanced non-small cell lung cancer who are performance status 2, based on a non-inferior survival and improved side effect profile. The previously scheduled June, 2009 meeting with the EMEA on OPAXIO did not occur due to conflicts in regulatory schedule as CTI focused on completing the pixantrone New Drug Application (NDA) submission in June, 2009.
"We are pleased that the EMEA has agreed to an in person oral explanation in September allowing the Company and its lung cancer experts adequate time to prepare a thorough review for the Co-rapporteurs in support of our MAA for OPAXIO in non-small cell lung cancer," said James A. Bianco, M.D., CEO of Cell Therapeutics. "The fourth quarter is shaping up to be a pivotal period for the Company."
About OPAXIO(TM)
OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.
About Cell Therapeutics, Inc. Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. |
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
1976 
54
